http://www.nootropic.eu sells low cost and legitimate Ebewe Neuro Pharma Cerebrolysin.
All our products are shipped from EU based pharmacy. We offer payments by PayPal, Google Checkout, UK/EU bank transfer. Delivery times within the EU: 5 to 15 working days, USA and Canada: 10 to 30 days.
Cerebrolysin, Mildronate. Piracetam, Pramiracetam, Neurobin - www.nootropic.eu
Therapeutic Applications: Improvement of cognitive and behavioral functions and in activities of daily living. Therapy Types: pharmacological: injectable peptide solution Mechanisms: Neuroprotection, neurotrophic agent, promotes neurogenesis, may decrease rate of apoptosis. FDA Phase: Approved outside U.S. Primary Medical Role: Treatment of Alzheimer's Disease Role in Alzheimer's Disease: Cerebrolysin is a peptide-based drug product supporting the survival, stability, and function of neurons. Cerebrolysin - www.nootropic.eu - decreases amyloid production, promotes synaptic repair, and improves cognitive and behavioral performance. Pharmacological Role: It is a peptidergic drug, produced from purified brain proteins by standardized enzymatic breakdown, containing biologically active peptides, is exerting nerve growth factor like activity on neurons from dorsal root ganglia. Neurotrophic and neuroprotective agent. It improves behavioral performance by affecting synaptic transmission in the hippocampus. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Side Effects: Cerebrolysin is generally well tolerated. If injected too quickly it may cause a moderate heat sensation. In extremely rare cases hypersensitivity reactions manifest themselves as chills, headaches, or slight increases in body temperature of the patient. In no case to date has the undesirable effect persisted or proved threatening to the patient’s health. Evidence pro its efficacy: Efficacy was demonstrated in randomized controlled clinical trials on different levels of clinical ailment by using standardized and validated assessment scales. Significant improvement of the patients was demonstrated in clinical global impression (CGI, CIBIC; 0.25–0.45 points), cognitive performance (MMSE, SKT, Trail-Making test, ADAS-cog [2–4 points]) and on the level of activities of daily living (NAI, DAD). Cerebrolysin has a fast onset of action (1 month) and beneficial effects are maintained up to 3 months after cessation of treatment. Companies: Ebewe Pharmaceutical Notes: Approved in 44 countries worldwide, for stroke, dementia, and traumatic brain injury. Cerebrolysin - www.nootropic.eu - is currently in Phase 3 in multiple countries in Europe.